Tag: Celyad
Celyad Oncology announces its intention to terminate its SEC reporting obligations – 02/08/2024 at 10:01 p.m.
Mont-Saint-Guibert, Belgium, February 8, 2024, 10:01 p.m. CET – privileged and regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that the Company will voluntarily…
Celyad Oncology provides an update on activities for the fourth quarter of 2023 and presents its outlook for 2024 – 01/16/2024 at 10:01 p.m.
Mont-Saint-Guibert, Belgium; January 16, 2024, 10:01 p.m. CET – Celyad Oncology (Euronext: CYAD) (the “Company”), today publishes an update of its activities for the fourth fiscal quarter of 2023, as…
Celyad announces a change of management – 01/12/2023 at 22:01
December 1, 2023, Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to the discovery and advancement of breakthrough technologies for chimeric antigen receptor (CAR) T cells…
Celyad Oncology: cash flow of 2.3 million, visibility until the 1st quarter of 2024 – 09/11/2023 at 1:35 p.m.
(AOF) – Celyad Oncology announces that as of September 30, 2023, it had cash and cash equivalents of 2.3 million euros. The biotech specializing in chimeric antigen receptor T cell…
Celyad Oncology announces the termination of its American Depositary Receipt program – 09/25/2023 at 10:01 p.m.
Mont-Saint-Guibert, Belgium, September 25, 2023, 10:01 p.m. CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces today that Citibank, NA, as depositary (“Citibank”),…
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights – 09/04/2023 at 10:00 PM
Mont-Saint-Guibert, Belgium, September 4, 2023, 10:00 p.m. CET, regulated information – Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”) today announces its financial results and recent developments business…
Celyad Oncology receives approximately EUR 9.8 million in private placement commitments from historical shareholders – 2023-08-24 22:00
Celyad Oncology SA (“Celyad” or the “Company”) announced today that it has obtained commitments from a subsidiary of Fortress Investment Group (such subsidiary, “Fortress”), Tolefi SA (“Tolefi”) and other historical…
Celyad Oncology: cash of 9.3 million euros at the end of March – 05/05/2023 at 16:45
(AOF) – Celyad Oncology announces that as of March 31, 2023, it had cash and cash equivalents of 9.3 million euros. Net cash consumption during the first quarter of 2023…
Celyad Oncology Reports 2022 Financial Results and Recent Highlights – 03/23/2023 at 22:01
Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell (CAR-T) therapies , today announces its financial…
Celyad Oncology will soon announce its 2022 operating and financial results and will hold a conference call – 03/17/2023 at 22:01
Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T cell therapies…
Celyad: financing guaranteed until the end of 2023 – 02/03/2023 at 14:42
(CercleFinance.com) – The biotechnology company Celyad estimated on Friday that its cash position of 12.4 million euros would not be sufficient to allow it to finance its expenses beyond the…
Celyad Oncology provides an update on its strategy…
By Arnaud Bives Published on 2022-12-21 at 07:46 (Boursier.com) — Celyad…